MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. Show more

Location: 11711 North Meridian Street, Carmel, IN, 46032, United States | Website: https://mbxbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

388.1M

52 Wk Range

$4.81 - $27.50

Previous Close

$11.61

Open

$11.65

Volume

425,670

Day Range

$11.47 - $12.42

Enterprise Value

140.7M

Cash

240.8M

Avg Qtr Burn

-16.66M

Insider Ownership

3.12%

Institutional Own.

-

Qtr Updated

03/31/25